A pharmacokinetic study of clazosentan in patients with aneurysmal subarachnoid haemorrhage

The objective of this study was to evaluate the pharmacokinetics of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage (aSAH) intravenous. Blood samples were taken at different time points during and following infusion with 0.2–0.4mg/kg/h clazosentan, which lasted for up to 14 days. The results show that the pharmacokinetic properties of clazosentan in patients with aSAH are similar to those in healthy subjects. With increasing body weight, higher plasma concentrations were reached, suggesting that clazosentan in future clinical studies can be dosed on a mg/h rather than a mg/kg/h basis.